IRVINE, Calif., Feb. 29 /PRNewswire-FirstCall/ -- NuRx Pharmaceuticals
Inc. (OTC Bulletin Board: NURX) today announced it has retained Russo
Partners LLC for the provision of investor relations and corporate
communications counsel.
The healthcare communications firm will implement a comprehensive
program that consists of investor targeting, the scheduling of
presentations at industry conferences, media relations and other corporate
visibility initiatives. Russo Partners will collaborate with OTC
Communications, a division of Rx Communications Group LLC, on the
implementation of some program tactics.
"We are in a unique position with a clinical-stage pipeline and large
portfolio of retinoid and rexinoid compounds that were developed over a
number of years by world-class researchers who have joined the NuRx
scientific team," said Harin Padma-Nathan, M.D., NuRx's president and CEO.
"We intend to initiate three to four clinical trials this year. Therefore,
the need to support the associated news flow prompted us to select Russo
Partners to develop and lead our communications efforts with Wall Street
and the biotech/pharmaceuticals community. The firm has the healthcare
industry expertise, senior-level talent and investor and media
relationships that were critical to our selection of a communications
partner."
Russo Partners LLC, formerly Noonan Russo, provides strategic
communications services to emerging healthcare - biotech, medical device,
diagnostics and healthcare services - companies worldwide. Headquartered in
New York City, the firm has a West Coast office in San Diego and an
affiliated office in London. For more information, visit
http://www.russopartnersllc.com.
NuRx Pharmaceuticals Inc. is an emerging biotech company focused on the
development of retinoid and rexinoid compounds with application in oncology
(treatment, prevention and adjunctive supportive therapy), the treatment of
diabetes, the regulation of lipid metabolism and bone metabolism and
repair. The company's lead compounds are (1) NRX4204, a highly specific,
first-in-class rexinoid agonist that is targeted for development in
non-small cell lung carcinoma and breast cancer; (2) NRX5183, a RAR alpha
subtype- specific agonist for the treatment of acute leukemia; and (3)
NRX4310, a function selective receptor modulator for the treatment and
prevention of chemotherapy-induced neutropenia. Located in Irvine, Calif.,
NuRx has a technology and IP platform that includes a library of nearly
6,000 compounds supported by 230 issued U.S. and international patents and
more than 80 additional patents in application. For more information, visit
http://www.nurxpharmaceutical.com.
The above information contains information relating to the Company that
is based on the beliefs of the Company and/or its management as well as
assumptions made by and information currently available to the Company or
its management. The Company, from time to time, may discuss forward-looking
information. Except for the historical information contained in this news
release, all forward-looking statements are predictions by the Company's
management and are subject to various risks and uncertainties that may
cause results to differ from management's current expectations. Such
factors include the fact that the Company is engaged in early stage
research and does not expect to obtain any revenues for several years and
other risks as detailed from time to time in the Company's registration
statement and reports and filings with the Securities and Exchange
Commission. All forward-looking statements, if any, in this news release
represent the Company's judgment as of the date of this news release. The
Company disclaims, however, any intent or obligation to update
forward-looking statements.
CONTACTS: Media
David Schull
(212) 845-4271
david.schull@russopartnersllc.com
Investors
Rhonda Chiger
(917) 322-2569
rchiger@rxir.com
SOURCE NuRx Pharmaceuticals Inc.
 back to top
Related links:
http://www.nurxpharmaceutical.com
http://www.russopartnersllc.com
CONTACT:
Media: David Schull, +1-212-845-4271,
david.schull@russopartnersllc.com ; Investors: Rhonda Chiger,
+1-917-322-2569, rchiger@rxir.com, both for NuRx Pharmaceuticals
Inc.
|
